



Artisan Global Opportunities Fund

MONTHLY
Commentary

Investor Class: ARTRX | Advisor Class: APDRX

As of 31 January 2019

Commentary

Markets rose in relatively uniform fashion in January—led by emerging markets, which were followed closely by the US and foreign developed markets—as investors largely put aside concerns that plagued much of 2018. As the month ended, the US Fed soothed investors' nerves, indicating signs of softer economic growth would lead to a pause in rate hikes for now. Sector returns were uniformly positive, with the energy sector among the top performers as it bounced back along with oil prices. Utilities, health care and staples were the bottom performers. From a style perspective, growth outperformed value, and smaller stocks generally outperformed their larger counterparts.

Our portfolio was solidly in the black but modestly trailed the MSCI AC World Index in January. Among our relatively few negative contributors in the month were Genmab and HDFC Bank. Genmab's Darzalex™ continues to be embraced as an effective therapy for multiple myeloma—though the drug's growth has moderated after a strong initial launch, weighing on shares. However, we expect strong clinical trial results in first-line multiple myeloma reported in Q4 to drive a reacceleration in 2019.

As discussed in our recent quarterly commentary, HDFC Bank has stood out as a solid Indian bank with particularly good governance and underwriting standards. Though shares modestly consolidated recent gains as the company reported quarterly results that were in line with expectations, we maintain our conviction in the franchise's quality and outlook.

Among our top contributors in January were Aptiv and Fevertree. Aptiv is executing well against a challenging auto backdrop. On the strength of its market-leading products, Aptiv is capitalizing on accelerating uptake for its advanced driver assistance systems (ADAS) and high-voltage electrification solutions to take market share. On the strength of the secular trend toward electric vehicles still ahead, we believe Aptiv is well-positioned to expand margins and drive an accelerating profit cycle. Further, given this combination of factors and solid intermediate-term growth prospects, the valuation is currently very attractive in our estimation.

Shares of Fevertree bounced back nicely in January after retrenching in Q4. Though growth in the UK is likely to moderate as the market matures, there is tremendous potential in the US as well as Europe—both sizeable markets which remain meaningfully underpenetrated. We maintain our conviction in the runway ahead of this well-managed franchise.

Our process is focused on identifying franchises exposed to accelerating profit cycles with reasonable valuations. It is our belief that owning companies with these characteristics should lead to outperformance over full market cycles. We will continue to adhere to this approach, regardless of the macro backdrop and how it evolves in the period ahead.

Portfolio Details

	ARTRX	APDRX
Net Asset Value (NAV)	\$23.52	\$23.63
Inception	22 Sep 2008	1 Apr 2015
Expense Ratios		
Annual Report 30 Sep 2018	1.15%	1.00%
Prospectus 30 Sep 2018 ¹	1.15%	1.01%

¹See prospectus for further details.

Top 10 Holdings (% of total portfolio)

IHS Markit Ltd (United States)	6.7
Visa Inc (United States)	4.6
Bank of America Corp (United States)	3.8
Techtronic Industries Co Ltd (Hong Kong)	3.6
Boston Scientific Corp (United States)	3.5
Anthem Inc (United States)	3.1
AstraZeneca PLC (United Kingdom)	3.0
Alphabet Inc (United States)	2.7
Aptiv PLC (United States)	2.7
Tencent Holdings Ltd (China)	2.6
TOTAL	36.3%

Source: Artisan Partners/FactSet (MSCI).

Sector Diversification (% of total portfolio equities)

	Fund
Communication Services	12.1
Consumer Discretionary	16.5
Consumer Staples	4.1
Energy	2.7
Financials	11.5
Health Care	19.0
Industrials	12.6
Information Technology	20.5
Materials	1.0
Real Estate	0.0
Utilities	0.0
TOTAL	100.0%

Source: Artisan Partners/FactSet (GICS). Cash and cash equivalents represented 5.8% of the total portfolio.

Investment Results (%)

As of 31 January 2019	Average Annual Total Returns							
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTRX	7.79	7.79	7.79	-8.86	13.09	8.88	16.23	10.36
Advisor Class: APDRX	7.80	7.80	7.80	-8.69	13.23	8.99	16.29	10.41
MSCI All Country World Index	7.90	7.90	7.90	-7.48	11.62	6.72	11.28	6.56
As of 31 December 2018								
Investor Class: ARTRX	-6.35	-15.45	-9.07	-9.07	7.70	6.62	14.69	9.64
Advisor Class: APDRX	-6.32	-15.39	-8.93	-8.93	7.85	6.72	14.75	9.70
MSCI All Country World Index	-7.04	-12.75	-9.41	-9.41	6.60	4.26	9.46	5.83

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized. Class inception: Investor (22 September 2008); Advisor (1 April 2015). For the period prior to inception, Advisor Class performance is the Investor Class's return for that period ("Linked Performance"). Linked Performance has not been restated to reflect expenses of the Advisor Class and the share class's returns during that period would be different if such expenses were reflected.

Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance. Performance may reflect agreements to limit a Fund's expenses, which would reduce performance if not in effect.

Region/Country Allocation (% of total portfolio equities)

REGION	Fund
AMERICAS	56.0
United States	56.0
EUROPE	26.0
United Kingdom	8.7
Switzerland	5.4
Denmark	3.2
France	2.3
Spain	1.9
Germany	1.9
Netherlands	1.6
Belgium	1.0
PACIFIC BASIN	12.0
Hong Kong	5.4
Japan	4.6
Australia	2.0
EMERGING MARKETS	6.0
China	2.8
India	2.4
Brazil	0.9
MIDDLE EAST	—
TOTAL	100.0%

Source: Artisan Partners/FactSet (MSCI).

Team Leadership (Pictured left to right)



Portfolio Managers	Years of Investment Experience
James D. Hamel, CFA (Lead)	22
Matthew H. Kamm, CFA	19
Craigh A. Cepukenas, CFA	30
Jason L. White, CFA	19

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period.

MSCI All Country World Index measures the performance of developed and emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 31 Jan 2019: Fevertree Drinks PLC 2.0%; Genmab A/S 2.1%; HDFC Bank Ltd 2.3%. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

Unless otherwise indicated, all information in this report includes all classes of shares, except performance and expense ratio information, and is as of the date shown in the upper right hand corner. Totals may not sum due to rounding.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

The Global Industry Classification Standard (GICS[®]) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

Country exposure percentages reflect country designations as classified by MSCI as of the date shown. Securities not classified by MSCI reflect country designations as of the date the report was generated. Sector exposure percentages reflect sector designations as currently classified by GICS.

Our capital allocation process is designed to build position size according to our conviction. Portfolio holdings develop through three stages: GardenSM, CropSM and HarvestSM. GardenSM investments are situations where we believe we are right, but there is not clear evidence that the profit cycle has taken hold, so positions are small. CropSM investments are holdings where we have gained conviction in the company's profit cycle, so positions are larger. HarvestSM investments are holdings that have exceeded our estimate of intrinsic value or holdings where there is a deceleration in the company's profit cycle. HarvestSM investments are generally being reduced or sold from the portfolios.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2019 Artisan Partners. All rights reserved.

2/5/2019 A19516L_vR